Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules

Area of Science:

• Immunology
• Oncology
• Gene Therapy

Background:

• T-cell receptor (TCR) gene transfer offers potent tumor targeting but is often limited by HLA-A2 restriction.
• Existing TCR therapies face challenges including potential adverse events and limited patient eligibility.
• Expanding TCR gene therapy requires targeting tumor-specific antigens across diverse human leukocyte antigen (HLA) types.

Purpose of the Study:

• To develop novel T-cell receptors (TCRs) targeting the cancer-testis antigen NY-ESO-1.
• To enable TCR gene therapy for a broader patient population by overcoming HLA-A2 restriction.
• To pilot an approach for targeting NY-ESO-1 in patients with diverse HLA haplotypes.

Main Methods:

• Isolation of TCRs specific for NY-ESO-1 epitopes presented by multiple HLA molecules (HLA-A2, -B07, -B18, -C03).
• Characterization of TCRs for specificity and efficacy against NY-ESO-1 expressing tumor cells.
• Evaluation of TCR gene transfer strategies for broader applicability.

Main Results:

• Successfully isolated TCRs targeting NY-ESO-1 presented by HLA-A2, -B07, -B18, and -C03.
• Demonstrated the potential to extend NY-ESO-1 targeted TCR gene therapy beyond HLA-A2 expressing patients.
• Established a framework for developing TCRs against public antigens for diverse HLA types.

Conclusions:

• NY-ESO-1 is a viable target for TCR gene therapy across multiple HLA types.
• The developed TCRs can broaden the application of NY-ESO-1 targeted immunotherapies.
• This strategy enhances the potential for safe and effective TCR gene therapy in a larger patient cohort.